The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Updated KarMMa results: ide-cel in R/R myeloma
Larry D Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX, discusses the updated results from KarMMa (NCT03361748), a Phase III study evaluating the use of idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T-cell therapy in patients with relapsed/refractory (R/R) multiple myeloma. The updated results from KarMMa trial continue to demonstrate deep, durable responses with ide-cel in heavily pretreated patients with R/R multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
